Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 392 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Cancer Research UK thanks Tania Bryer for a decade of fundraising... April 19, 2022 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... January 20, 2025 Load more HOT NEWS Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... Record Impact Factor for Annals of Oncology Highlights Growing Influence of... Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening
